Circular RNA SLC26A4 regulates the maturation of microRNA‑15a in non‑small cell lung cancer cells

Chen,Qiankun; Li,Hua; Liu,Ji

doi:10.3892/ol.2021.12983

Circular RNA SLC26A4 regulates the maturation of microRNA‑15a in non‑small cell lung cancer cells

Authors:
- Qiankun Chen
- Hua Li
- Ji Liu
View Affiliations

Affiliations: Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200433, P.R. China, Department of Anesthesiology, Shanghai Pulmonary Hospital, Shanghai 200433, P.R. China
Published online on: August 10, 2021 https://doi.org/10.3892/ol.2021.12983
Article Number: 722
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To the best of our knowledge, the oncogenic role of circular RNA solute carrier family 26 member 4 (circSLC26A4) has only been reported in cervical cancer, while its role in non‑small cell lung cancer (NSCLC) is unknown. The present study explored the involvement of circSLC26A4 in NSCLC. NSCLC tissues and paired adjacent non‑tumor tissues were collected from 64 patients with NSCLC. The expression levels of circSLC26A4, mature microRNA‑15a (miR‑15a) and miR‑15a precursor in these tissues were determined by reverse transcription‑quantitative PCR (RT‑qPCR). NSCLC cells were transfected with pcDNA3.1‑circSLC26A4 vector to overexpress circSLC26A4, followed by the measurement of the expression levels of mature miR‑15a and miR‑15a precursor using RT‑qPCR. Cell proliferation was analyzed using a Cell Counting Kit‑8 assay. circSLC26A4 expression was upregulated in NSCLC tissues, and its high expression was significantly associated with poor survival of patients with NSCLC. The expression levels of circSLC26A4 were correlated with the expression levels of mature miR‑15a, but not the expression levels of miR‑15a precursor in NSCLC tissues. In NSCLC cells, overexpression of circSLC26A4 was associated with downregulation of mature miR‑15a expression, but not miR‑15a precursor expression. A cell proliferation assay revealed that overexpression of circSLC26A4 reduced the inhibitory effects of overexpression of miR‑15a on cell proliferation. Therefore, circSLC26A4 may suppress the maturation of miR‑15a in NSCLC to inhibit cancer cell proliferation.

View Figures

View References

1	Adjei AA: Lung cancer worldwide. J Thorac Oncol. 14:9562019. View Article : Google Scholar : PubMed/NCBI
2	Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG and Shepherd FA: Non-small-cell lung cancer. Lance. 378:1727–1740. 2011. View Article : Google Scholar : PubMed/NCBI
3	Jamal-Hanjani M, Wilson GA, McGranahan N, Brikbak N, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, et al: Tracking the evolution of non-small-cell lung cancer. N Engl J Med. 376:2109–2121. 2017. View Article : Google Scholar : PubMed/NCBI
4	Chan BA and Hughes BG: Targeted therapy for non-small cell lung cancer: Current standards and the promise of the future. Transl Lung Cancer Res. 4:36–54. 2015.PubMed/NCBI
5	Janku F, Stewart DJ and Kurzrock R: Targeted therapy in non-small-cell lung cancer-is it becoming a reality? Nat Rev Clin Oncol. 7:401–414. 2010. View Article : Google Scholar : PubMed/NCBI
6	Herbst RS, Morgensztern D and Boshoff C: The biology and management of non-small cell lung cancer. Nature. 553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
7	Hirsch FR, Suda K, Wiens J and Bunn PA Jr: New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 388:1012–1024. 2016. View Article : Google Scholar : PubMed/NCBI
8	Joseph AM, Rothman AJ, Almirall D, Begnaud A, Chiles C, Cinciripini PM, Fu SS, Graham AL, Lindgren BR, Melzer AC, et al: Lung cancer screening and smoking cessation clinical trials. SCALE (smoking cessation within the context of lung cancer screening) collaboration. Am J Respir Crit Care Med. 197:172–182. 2018. View Article : Google Scholar : PubMed/NCBI
9	Saito S, Espinoza-Mercado F, Liu H, Sata N, Cui X and Soukiasian HJ: Current status of research and treatment for non-small cell lung cancer in never-smoking females. Cancer Biol Ther. 18:359–368. 2017. View Article : Google Scholar : PubMed/NCBI
10	Eser PÖ and Jänne PA: TGFβ pathway inhibition in the treatment of non-small cell lung cancer. Pharmacol Ther. 184:112–130. 2018. View Article : Google Scholar : PubMed/NCBI
11	Tomasini P, Walia P, Labbe C, Jao K and Leighl NB: Targeting the KRAS pathway in non-small cell lung cancer. Oncologist. 21:1450–1460. 2016. View Article : Google Scholar : PubMed/NCBI
12	Zhou R, Wu Y, Wang W, Su W, Liu Y, Wang Y, Fan C, Li X, Li G, Li Y, et al: Circular RNAs (circRNAs) in cancer. Cancer Lett. 425:134–142. 2018. View Article : Google Scholar : PubMed/NCBI
13	Meng S, Zhou H, Feng Z, Xu Z, Tang Y, Li P and Wu M: CircRNA: Functions and properties of a novel potential biomarker for cancer. Mol Cancer. 16:942017. View Article : Google Scholar : PubMed/NCBI
14	Ji F, Du R, Chen T, Zhang M, Zhu Y, Luo X and Ding Y: Circular RNA circSLC26A4 accelerates cervical cancer progression via miR-1287-5p/HOXA7 axis. Mol Ther Nucleic Acids. 19:413–420. 2020. View Article : Google Scholar : PubMed/NCBI
15	He J: Knocking down miR-15a expression promotes the occurrence and development and induces the EMT of NSCLC cells in vitro. Saudi J Biol Sci. 24:1859–1865. 2017. View Article : Google Scholar : PubMed/NCBI
16	Detterbeck FC, Boffa DJ, Kim AW and Tanoue LT: The eighth edition lung cancer stage classification. Chest. 151:193–203. 2017. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-timequantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Stokes WA, Bronsert MR, Meguid RA, Blum MG, Jones BL, Koshy M, Sher DJ, Louie AV, Palma DA, Senan S, et al: Post-treatment mortality after surgery and stereotactic body radiotherapy for early-stage non-small-cell lung cancer. J Clin Oncol. 36:642–651. 2018. View Article : Google Scholar : PubMed/NCBI
19	Goyal G, Kommalapati A, Bartley AC, Gunderson TM, Adjei AA and Go RS: Association between hospital volume and mortality of patients with metastatic non-small cell lung cancer. Lung Cancer. 122:214–219. 2018. View Article : Google Scholar : PubMed/NCBI
20	Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, Escriu C and Peters S; ESMO Guidelines Committee, : Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 28 (Suppl-4):iv1–iv21. 2017. View Article : Google Scholar : PubMed/NCBI
21	Lan F, Yue X, Ren G, Li H, Ping L, Wang Y and Xia T: miR-15a/16 enhances radiation sensitivity of non-small cell lung cancer cells by targeting the TLR1/NF-κB signaling pathway. Int J Radiat Oncol Biol Phys. 91:73–81. 2015. View Article : Google Scholar : PubMed/NCBI
22	Bozok Çetintaş V, Tetik Vardarlı A, Düzgün Z, Tezcanlı Kaymaz B, Açıkgöz E, Aktuğ H, Kosova Can B, Gündüz C and Eroğlu Z: miR-15a enhances the anticancer effects of cisplatin in the resistant non-small cell lung cancer cells. Tumour Biol. 37:1739–1751. 2016. View Article : Google Scholar
23	Guo S, Li M, Li J and Lv Y: Inhibition mechanism of lung cancer cell metastasis through targeted regulation of Smad3 by miR-15a. Oncol Lett. 19:1516–1522. 2020.PubMed/NCBI
24	Yang T, Thakur A, Chen T, Chen T, Yang L, Lei G, Liang Y, Zhang S, Ren H and Chen M: MicroRNA-15a induces cell apoptosis and inhibits metastasis by targeting BCL2L2 in non-small cell lung cancer. Tumour Biol. 36:4357–4365. 2015. View Article : Google Scholar : PubMed/NCBI
25	Pickering BF, Yu D and Van Dyke MW: Nucleolin protein interacts with microprocessor complex to affect biogenesis of microRNAs 15a and 16. J Biol Chem. 286:44095–44103. 2011. View Article : Google Scholar : PubMed/NCBI